HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

Syl930

an agonist of sphingosine-1-phosphate receptor subtype 1; structure in first source

Networked: 3 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Oxazoles: 89
      - Syl930: 3
Organic Chemicals: 133
- Amines: 4871
  - Amino Alcohols: 20
    - Propanolamines: 4
      - Syl930: 3
- Alcohols: 595
  - Amino Alcohols: 20
    - Propanolamines: 4
      - Syl930: 3
  - Propanols: 3
    - Propanolamines: 4
      - Syl930: 3

Experts

1.	Jin, Jing: 3 articles (04/2018 - 07/2014)
2.	Chen, Xiaoguang: 2 articles (04/2018 - 07/2014)
3.	Xue, Nina: 2 articles (04/2018 - 07/2014)
4.	Hu, Jinping: 2 articles (02/2017 - 07/2014)
5.	Wang, Xiaojian: 2 articles (02/2017 - 07/2014)
6.	Xiao, Qiong: 2 articles (02/2017 - 07/2014)
7.	Ji, Ming: 1 article (04/2018)
8.	Lai, Fangfang: 1 article (04/2018)
9.	Wang, Yuchen: 1 article (04/2018)
10.	Zhang, Sen: 1 article (04/2018)

Related Diseases

1.	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 07/01/2014 - "In this study, we further investigated the therapeutic potential of Syl930 on an experimental autoimmune encephalomyelitis (EAE) model in Lewis rats. "
2.	Autoimmune Diseases of the Nervous System 07/01/2014 - "These results illustrate that, as a selective S1P1 agonist, Syl930 exhibits a profound and rapidly reversible suppression of lymphocyte trafficking and it has the potential to serve as a therapeutic agent for autoimmune encephalitis. " 07/01/2014 - "Development of a selective S1P1 receptor agonist, Syl930, as a potential therapeutic agent for autoimmune encephalitis." 02/01/2017 - "Syl930 is a novel sphingosine-1-phosphate receptor subtype 1 (S1PR1) agonist for the treatment of autoimmune encephalitis with promising receptor selectivity and little risk of bradycardia. " 02/01/2017 - "Identification of cytochrome P450 isoforms involved in the metabolism of Syl930, a selective S1PR1 agonist acting as a potential therapeutic agent for autoimmune encephalitis."
3.	Psoriasis (Pustulosis Palmaris et Plantaris) 04/01/2018 - "Here, we test a newly developed selective S1P1 modulator, Syl930, in four different psoriasis animal models. " 04/01/2018 - "Therefore, we demonstrate that Syl930 is a promising candidate for psoriasis therapy in clinical." 04/01/2018 - "Validating a Selective S1P1 Receptor Modulator Syl930 for Psoriasis Treatment." 04/01/2018 - "Moreover, Syl930 can ameliorate the parakeratosis and acanthosis as well as improve granular layer composition and decrease the thickening of epidermis in a propranolol-induced guinea pig psoriasis model. "
4.	Parakeratosis 04/01/2018 - "Moreover, Syl930 can ameliorate the parakeratosis and acanthosis as well as improve granular layer composition and decrease the thickening of epidermis in a propranolol-induced guinea pig psoriasis model. "
5.	Bradycardia 02/01/2017 - "Syl930 is a novel sphingosine-1-phosphate receptor subtype 1 (S1PR1) agonist for the treatment of autoimmune encephalitis with promising receptor selectivity and little risk of bradycardia. "

Related Drugs and Biologics

1.	Sphingosine-1-Phosphate Receptors
2.	Protein Isoforms (Isoforms)
3.	Propranolol (Inderal)
4.	Cytochrome P-450 Enzyme System (Cytochrome P450)

Related Therapies and Procedures

1.	Therapeutics